{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}],"title":"Alive"},{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Deceased"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Unknown/Lost to Follow Up"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Summary report of patient status at the end of the study period. Duration of survival was calculated, however, median survival time for OS has not yet been reached, and therefore is not reported here.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Clinical Outcomes: Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Participants"}